Table 2.
Age- and sex-adjusted relative levels of serum YKL-40 and IL-6 in healthy subjects (N=245 for YKL-40 and N=348 for IL-6) and patients with pre-treatment (N=176) and treated (N=29) Hodgkin lymphoma. For reference, relative levels were compared to serum levels estimated for healthy 35 years old women: 39 ng/mL for YKL-40 and 1.3 pg/mL for IL-6.
| YKL-40 | IL-6 | |
|---|---|---|
| Healthy controls | ||
| Increase per decade | 1.15 (1.12−1.19) | 1.07 (1.00−1.15) |
| Males compared to females | 0.92 (0.82−1.04) | 1.15 (0.98−1.34) |
| Relative serum levels in pre-treatment patients with Hodgkin lymphoma compared to healthy controls* | ||
| Overall HL | 3.63 (3.10−4.24) | 8.32 (5.94−11.7) |
| Histology | ||
| Nodular sclerosis | 3.73 (3.13−4.46) | 9.00 (6.26−12.9) |
| Mixed cellularity | 3.15 (1.93−5.14) | 8.42 (3.28−21.6) |
| Other/undefined | 3.40 (2.32−4.98) | 6.06 (1.91−19.2) |
| Ann Arbor Stage | ||
| 1 | 3.42 (2.35−4.98) | 8.28 (2.60−26.4) |
| 2 | 3.28 (2.74−3.92) | 5.95 (3.91−9.06) |
| 3 | 4.23 (2.89−6.20) | 14.97 (7.28−30.8) |
| 4 | 4.20 (2.24−7.90) | 20.42 (6.58−63.4) |
| ptrend <0.0001 | ptrend = 0.013 | |
| Serum level ≥6 months after treatment onset compared to pre-treatment level** | ||
| Overall HL | 70% (53%−91%) | 47% (26%−83%) |
| Nodular sclerosis | 69% (50%−95%) | 30% (15%−58%) |
| Mixed cellularity | 79% (44%−141%) | 98% (33%−291%) |
| Other/undefined | 52% (24%−113%) | 112% (11%−1152%) |
*
Relative to age- and sex-adjusted levels in healthy controls.
**
Difference relative to median serum levels in untreated patients, after age- and sex-adjustment. For example, in HL patients, median levels for YKL-40 were 70% of those seen in pre-treatment patients, after age- and sex-adjustment.